NCT00471978

Brief Summary

RATIONALE: Studying samples of blood and tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help the study of cancer in the future. PURPOSE: This clinical trial is analyzing the DNA in blood and tissue samples from patients with lung cancer.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Timeline
3mo left

Started Sep 2005

Longer than P75 for all trials

Geographic Reach
1 country

2 active sites

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress99%
Sep 2005Sep 2026

Study Start

First participant enrolled

September 1, 2005

Completed
1.7 years until next milestone

First Submitted

Initial submission to the registry

May 8, 2007

Completed
2 days until next milestone

First Posted

Study publicly available on registry

May 10, 2007

Completed
19.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2026

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2026

Last Updated

November 29, 2024

Status Verified

November 1, 2024

Enrollment Period

21 years

First QC Date

May 8, 2007

Last Update Submit

November 26, 2024

Conditions

Lung Cancer

Keywords

non-small cell lung cancersmall cell lung cancerpulmonary carcinoid tumor

Outcome Measures

Primary Outcomes (1)

  • Metabolic polymorphisms

    to compare differences among lung cancer patients

    10 years

Eligibility Criteria

Age18 Years - 120 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
DISEASE CHARACTERISTICS: * Patient: * Newly diagnosed primary lung cancer * Patient at Massachusetts General Hospital (MGH) or Boston Medical Center Cancer Center PATIENT CHARACTERISTICS: * Not specified PRIOR CONCURRENT THERAPY: * Not specified EXCLUSIONS: Vulnerable populations are excluded. Patients with metastasis from another site to lung or mesothelioma are excluded.

Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.

Sponsors & Collaborators

Study Sites (2)

Massachusetts General Hospital

Boston, Massachusetts, 02114, United States

RECRUITING

Harvard School of Public Health

Boston, Massachusetts, 02115, United States

RECRUITING

MeSH Terms

Conditions

Lung NeoplasmsCarcinoma, Non-Small-Cell LungSmall Cell Lung Carcinoma

Condition Hierarchy (Ancestors)

Respiratory Tract NeoplasmsThoracic NeoplasmsNeoplasms by SiteNeoplasmsLung DiseasesRespiratory Tract DiseasesCarcinoma, BronchogenicBronchial Neoplasms

Study Officials

  • David C. Christiani, MD

    Massachusetts General Hospital

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Elkan Blout Professor of Enviromental Genetics, Professor of Medicine

Study Record Dates

First Submitted

May 8, 2007

First Posted

May 10, 2007

Study Start

September 1, 2005

Primary Completion (Estimated)

September 1, 2026

Study Completion (Estimated)

September 1, 2026

Last Updated

November 29, 2024

Record last verified: 2024-11

Data Sharing

IPD Sharing
Will not share

Locations

US(2)